智通财经APP获悉，微创系集体飙升，截至发稿，微创脑科学(02172)涨20.4%，报13.1港元；微创医疗(00853)涨14.58%，报8.88港元；微创机器人-B(02252)涨1.97%，报20.7港元；心通医疗-B(02160)涨1.82%，报1.12港元。
小摩此前发布研报称，微创机器人的订单趋势强劲，亦属微创医疗旗下重要的子公司，预计由于中国和海外机器人安装的快速扩张，前者对集团销售贡献将由2024年约3%升至2033年约40%。该行重申对微创医疗积极看法，在中小型医疗技术领域(SMID)中集团是多元化本地领导者，具有强大的创新能力、海外市场扩张，并且预计至2026年可扭亏为盈；又指集团仍然是该行在SMID医疗技术领域的首选。
野村表示，从微创医疗2024财年初步业绩来看，收入实现了同比10%的增长，但这一数字低于此前指引的17%。盈利方面，亏损同比收窄幅度超过58%，至小于2.75亿美元，主要得益于公司持续推行成本控制策略，有效降低了运营成本；以及撤资非核心业务获得收益。展望未来，野村预计微创医疗在2025和2026财年可能会继续实施节省成本的措施，特别是考虑到目前销售额仍未达理想水平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.